FDA ODE III permanent director
FDA's Office of Drug Evaluation III will be led on a permanent basis by Julie Beitz, FDA announces Oct 25. Beitz, formerly ODE III deputy director, has been acting director since former director Florence Houn went on detail to the Office of Compliance in January. Houn is now deputy director of CBER's Office of Vaccines. Divi-sion of Reproductive & Urologic Products Director Daniel Shames has been serving as acting deputy director of ODE III...
You may also be interested in...
France plans to begin issuing manufacturing quality certificates so firms can import ordinary cosmetics into China without animal testing under a 2020 draft regulation. The Personal Care Products Council is working to find a comparable solution for US manufacturers.
The calcineurin inhibitor, only the second drug to be approved by the US FDA for lupus nephritis, will be competing against GlaxoSmithKline’s Benlysta.
Federal prosecutors’ latest criminal case alleging fraudulent advertising and sales of vitamins and other nutrients available nonprescription in the US as remedies for infections from the novel coronavirus is against Johnny Stine, owner and operator of North Coast Biologics in Seattle.